Trial Profile
A Phase 1b Safety and Feasibility Study of Personalized Immunotherapy in Adults With Advanced Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 30 Dec 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2025.
- 16 May 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.